AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia
MLN4924, Nedd8-activating enzyme inhibitor, is administered intravenously on days 1, 3 and 5 of a 21 day cycle in patients with AML and high-grade myelodysplastic syndrome.
SAR 3419 is a conjugate consisting of monoclonal antibody targeting CD19 and cytotoxic maytansine derivate. In this phase II study SAR 3419 is administered intravenously weekly in patients with relapsed or refractory acute lymphoblastic leukemia (ALL)